Specific RNA aptamers to NS3 protease domain of hepatitis C virus
Fukuda, K.; Vishinuvardhan, D.; Sekiya, S.; Kakiuchi, N.; Shimotohno, K.; Kumar, P.K.; Nishikawa, S.
Nucleic Acids Symposium Series 37: 237-238
1997
ISSN/ISBN: 0261-3166 PMID: 9586087 Document Number: 470612
In order to isolate RNA aptamers that bind specifically to NS3 protease domain (delta NS3) of hepatitis C virus, we carried out in vitro selection procedure using RNA pool that had 30 N random core region. After repeating nine cycles of selections and amplifications, a pool of RNAs that bind specifically to the delta NS3 were selected. A comparative analysis of 45 clones that were isolated from 9th cycle revealed three main classes that contain the conserved loop sequences GANUGGGAC. Moreover, the predominant class of aptamer (class I and III) appear to inhibit the protease activity efficiently.
Document emailed within 1 workday
Related Documents
Sovová, V.; Trávnícek, M.; Hlozánek, I.; Cerná, H.; Sulová, A. 1984: Analysis of gag-myc proteins of partially transformation-defective mutants of avian myelocytomatosis virus strain MC29 by in vitro cleavage with protease p15: indication for the presence of specific cleavage site p15 in the myc domain of fusion protein Folia Biologica 30(3): 145-151Saves, M.; Raffi, F.; Clevenbergh, P.; Marchou, B.; Waldner-Combernoux, A.; Morlat, P.; LeMoing, V.; Riviere, C.; Chene, G.; Leport, C.; The APROCOStudy Group, 2000: Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients Antimicrobial Agents and Chemotherapy 44(12): 3451-3455
Lei, C.-l.; Huang, C.-h.; Yang, Z.; Tang, X.-p. 2007: Induction of specific cytotoxic T lymphocyte response against hepatitis B virus by hepatitis B virus S gene-modified dendritic cells Zhonghua Shi Yan he Lin Chuang Bing du Xue Za Zhi 21(2): 108-110
Son, H.-C.; Yoon, M.-S.; Kim, Y.-J.; Kim, I.-H.; Kim, Y.-S. 2002: Type-specific antibody for hepatitis C virus detected by use of NS-4 peptide and hepatitis C virus genome in Korea Rinsho Byori. Japanese Journal of Clinical Pathology 50(5): 533-540
Armignacco, O.; Andreoni, M.; Sagnelli, E.; Puoti, M.; Bruno, R.; Gaeta, G.Battista.; Perno, C.F.; Santantonio, T.A.; Bonfanti, P.; Bonora, S.; Borderi, M.; Castagna, A.; d'Arminio Monforte, A.; De Luca, A.; Grossi, P.; Guaraldi, G.; Maggiolo, F.; Mussini, C.; Sagnelli, C.; Tavio, M.; Torti, C.; Uberti-Foppa, C.; Andreoni, M.; Angarano, G.; Antinori, A.; Armignacco, O.; Carosi, G.; Chirianni, A.; Di Perri, G.; Galli, M.; Lazzarin, A.; Rizzardini, G.; Sagnelli, E.; Taliani, G. 2014: Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease new microbiologica 37(4): 423-438
Lodrini, S.; Bagaglio, S.; Canducci, F.; De Mitri, M.S.; Andreone, P.; Loggi, E.; Lazzarin, A.; Clementi, M.; Morsica, G. 2003: Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus Journal of Biological Regulators and Homeostatic Agents 17(2): 198-204
Zabek, P.; Opoka-Kegler, J.; Baka, M.; Dyda, T.; Stańczak, G.P.; Stańczak, J.J. 2013: Prevalence of hepatitis C virus mutants resistant to protease inhibitors among Polish HCV genotype 1-infected patients Przeglad Epidemiologiczny 67(3): 411
Kakumu, S.; Ishikawa, T.; Wakita, T.; Yoshioka, K.; Takayanagi, M.; Tahara, H.; Kusakabe, A. 1994: Interferon-gamma production specific for hepatitis B virus antigen by intrahepatic T lymphocytes in patients with acute and chronic hepatitis B American Journal of Gastroenterology 89(1): 92-96
Dumortier, J.ér.ôm.; Chiarello, P.; Adham, M.; Delafosse, B.; Chayvialle, J.-A.; Scoazec, J.-Y.; Boillot, O. 2002: Specific risks of liver transplantation in patients co-infected with hepatitis C virus and human immunodeficiency virus Gastroenterologie Clinique et Biologique 26(11): 1061-1062
Lin, W.H.; Feng, H.-P.; Shadle, C.R.; O'Reilly, T.; Wagner, J.A.; Butterton, J.R. 2014: Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone European Journal of Clinical Pharmacology 70(9): 1107-1113
Sabo, J.P.; Lang, B.; Elgadi, M.; Huang, F. 2015: Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers Antimicrobial Agents and ChemoTherapy 59(1): 514-519
Yamaoka, T.; Ogawa, F.; Muroi, E.; Hara, T.; Komura, K.; Iwata, Y.; Takenaka, M.; Shimizu, K.; Hasegawa, M.; Fujimoto, M.; Sato, S. 2008: Autoantibody against a protease domain of caspase-8 in patients with systemic sclerosis Clinical and Experimental Rheumatology 26(6): 998-1004
Hwang, L.H.; Lin, Y.J.; Lai, W.C.; Lo, M.S. 1991: Protease-like sequence in hepatitis B virus core antigen is not involved in the cleavage processes of core protein in Escherichia coli Zhonghua Minguo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 24(1): 71-83
Sherman, K.E.; Shire, N.J.; Cernohous, P.; Rouster, S.D.; Omachi, J.H.; Brun, S.; Da Silva, B. 2005: Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients : Lopinavir-ritonavir versus nelfinavir Clinical Infectious Diseases 41(8): 1186-1195
Courcambeck, J.ér.ôm.; Bouzidi, M.; Perbost, R.ég.; Jouirou, B.; Amrani, N.; Cacoub, P.; Pèpe, G.ér.; Sabatier, J.-M.; Halfon, P. 2006: Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations Antiviral Therapy 11(7): 847-855
Kuru, U.; Senli, S.; Türel, L.; Kuru, N.; Başkent, A.; Ulucakli, O. 1995: Age-specific seroprevalence of hepatitis B virus infection Turkish Journal of Pediatrics 37(4): 331-338
Mel'kina, O.E.; Manukhov, I.V.; Zavil'gel'skiĭ, G.B. 2010: The C-terminal domain of the Vibrio fischeri transcription activator LuxR is not essential for degradation by Lon protease Molekuliarnaia Biologiia 44(3): 515-519
Sungkanuparph, S.; Vibhagool, A.; Manosuthi, W.; Kiertiburanakul, S.; Atamasirikul, K.; Aumkhyan, A.; Thakkinstian, A. 2004: Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study Journal of the Medical Association of Thailand 87(11): 1349-1354
Adoga, M.P.; Banwat, E.B.; Forbi, J.C.; Nimzing, L.; Pam, C.R.; Gyar, S.D.; Agabi, Y.A.; Agwale, S.M. 2009: Human immunonodeficiency virus, hepatitis B virus and hepatitis C virus: sero-prevalence, co-infection and risk factors among prison inmates in Nasarawa State, Nigeria Journal of Infection in Developing Countries 3(7): 539-547
Chung, D.C.; Ko, Y.C.; Chen, C.J.; Chen, E.R.; Wu, C.C.; Wu, P.S. 1989: Seroepidemiology of hepatitis B virus, hepatitis D virus, and human immunodeficiency virus infections among parenteral drug abusers in southern Taiwan Journal of Medical Virology 28(4): 215-218